Abstract
ABSTRACTPurpose The microRNAs expression has emerged as a potential biomarker for the diagnosis and prognosis of prostate cancer. This study investigated the expression of miRNA-182 and miRNA-187 in prostate cancer patients and established a correlation between miRNA expression and staging of prostate cancer.Materials and Methods This prospective observational study involved patients undergoing transrectal ultrasound-guided biopsy for suspicion of prostate cancer. Pre-biopsy urine samples and prostatic core tissue samples of the patients were preserved and the miRNA-182 and miRNA-187 were studied.Results Sixty-three patients were included in this study, thirty-three patients were diagnosed with prostate cancer and thirty patients having benign histopathology were considered as controls. The expression of miRNA-182 was significantly increased (p=0.002) and miRNA-187 significantly decreased (p <0.001) in prostate cancer tissue specimens. However, the expression of these miRNAs did not significantly differ in the urine of prostate cancer patients as compared to controls. Serum Prostatic Specific Antigen (PSA) inversely correlated with the median expression of miR-187 in prostatic tissue (p=0.002). Further, the expression of miRNA-187 in prostate cancer tissue was significantly decreased in metastatic prostate cancer (p=0.037). Using ROC analysis, miRNA-187 expression was able to distinguish the presence or absence of bone metastasis [area under ROC (AUROC) (±SD) was 0.873±0.061, p <0.001].Conclusion The miRNA-182 and miRNA-187 appear to be promising biomarkers in prostate cancer and miRNA-187 can serve as an important diagnostic marker of metastatic prostate cancer.
Highlights
Prostate cancer is among the common cancers of men and a major cause of cancer death
They can act as oncogenes and tumor suppressor genes, they are aberrantly expressed in human malignancies and play an important role in initiation, promotion, and metastases of these malignancies including prostate cancer [3]
MicroRNA in the urine, serum and prostatic tissue has emerged as a potential biomarker for prostate cancer diagnosis and staging
Summary
Prostate cancer is among the common cancers of men and a major cause of cancer death. Though serum PSA is widely used in clinical practice, a multitude of genomic markers has revolutionized the screening and management of prostate cancer [2]. This has led to an increased interest in the role of microRNAs (miRNAs) for the diagnosis of prostate cancer. The miRNAs are relatively small non-coding RNA molecules involved in cell development, differentiation, apoptosis, and cell proliferation They can act as oncogenes and tumor suppressor genes, they are aberrantly expressed in human malignancies and play an important role in initiation, promotion, and metastases of these malignancies including prostate cancer [3]. We evaluated the significance of urinary and tissue microRNAs (miRNA-182 and miRNA-187) in prostate cancer patients and their association with prostate cancer staging
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
